Original ArticleNon–Small Cell Lung CancerPneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Keywords
Cited by (0)
Disclosure: Dr. Voong reports grants from the Lung Cancer Research Foundation and Radiation Oncology Institute and personal fees from ASCO Advantage outside the submitted work. Dr. Forde reports grants from and service on an advisory board of Bristol-Myers Squibb, grants from and service on an advisory board of AstraZeneca, and grants from Novartis outside the submitted work. Dr. Ettinger reports personal fees from BeyondSpring Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, and Guardant Health and grants from Golden Biotech outside the submitted work. Dr. Marrone reports personal fees from Compugen and Takeda outside the submitted work. Dr. Kelly reports grants from and service on an advisory board of Bristol-Myers Squibb, grants from and service on an advisory board of Eli Lilly and Company, and service on a data monitoring committee and advisory board for Novartis outside the submitted work. Dr. Hann reports personal fees for advisory board participation and compensation to his institution for clinical trial participation from Bristol-Myers Squibb and personal fees for consultation from Genentech outside the submitted work. Dr. Levy reports personal fees from AstraZeneca, Celgene, Eli Lilly and Company, Genentech, and Takeda outside the submitted work. Dr. Brahmer reports an uncompensated advisory board participation and consultation arrangement with Bristol-Myers Squibb, grants from Bristol-Myers Squibb and AstraZeneca/MedImmune, and personal fees from Genentech during conduct of the study, as well as an uncompensated advisory board participation and consultation arrangement with Bristol-Myers Squibb, grants from Bristol-Myers Squibb and AstraZeneca/MedImmune, and personal fees from Genentech outside the submitted work. Dr. Naidoo reports grants and other from AstraZeneca, other from Bristol-Myers Squibb, grants from Merck, and other from Takeda outside the submitted work. The remaining authors declare no conflict of interest.